Results 221 to 230 of about 36,802 (283)

Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia? [PDF]

Cancer
Babu NS, Sangeetha KSS.
europepmc   +1 more source

Targeted Next-Generation Sequencing of JAK2, CALR, and MPL in 10 326 Patients With Suspected Myeloproliferative Neoplasm. [PDF]

Am J Hematol
Rigolot L, Chea M, Largeaud L, Prade N, Dufrechou S, Condom P, Lhossein T, Juvin PY, Riol J, Frébet E, Migné H, Legoff I, Boivert C, Daniau B, Gueudet P, Bories P, Huguet F, Tavitian S, Delabesse E, De Mas V.   +19 more
europepmc   +1 more source

An MRI-visible nanotheranostic establishes a self-amplifying pyroptosis-STING-IFN-β circuit for CD8⁺ T cell immunoactivation. [PDF]

Mater Today Bio
Jing P, Wang L, Qiu X, Chen L, Xie D, Yu Y, Li B, Yan S, Wang G, Zhong Z, Fu W.   +10 more
europepmc   +1 more source

Optimized Test Utilization Significantly Increased the Positive Detection Rate for Myeloproliferative Neoplasms. [PDF]

Cancers (Basel)
Nfonsam LE, Qi MZ, Butcher DT, Campbell CJV, Cocca A, Dalmia S, Davies GA, Hohenadel BA, McCready E.   +8 more
europepmc   +1 more source

Beyond the JAK2 mutation: The inflammasome, clonal stability, and the thrombotic niche in myeloproliferative neoplasms. [PDF]

Clin Exp Med
Abdelgawwad El-Sehrawy AAM, Al-Khreisat MJ, Kibriyeva M, Dilbar I, Axmedova F, Mohammed JA, Mishra S, Tailor NK.   +7 more
europepmc   +1 more source

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia. [PDF]

Am J Hematol
Loscocco GG, Gangat N, Guglielmelli P, Pardanani A, Vannucchi AM, Tefferi A.   +5 more
europepmc   +1 more source

Spectrum of Bone Marrow Pathological Findings in Patients Undergoing Bone Marrow Biopsy: A Cross-Sectional Study. [PDF]

Cureus
Arbi FM, Khan TI, Khan HI, Farani F.
europepmc   +1 more source

The bidirectional relationship between <i>JAK2V617F</i> allele burden and inflammation in polycythaemia vera: Insights from interferon and ruxolitinib therapy. [PDF]

Hemasphere
Barbui T, Guglielmelli P, Vannucchi AM.
europepmc   +1 more source

Immunogenetic and Transcriptomic Evidence Implicating the NKG2D-MICA/MICB Axis in CALR-Mutated Myeloproliferative Neoplasms. [PDF]

Cancers (Basel)
Shivarov V, Tsvetkova G, Micheva I, Hadjiev E, Petkova J, Madjarova G, Ivanova M.   +6 more
europepmc   +1 more source

Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms. [PDF]

J Hematol Oncol
Arora S, Senapati J, Deshmukh I, Bose P, Masarova L, Loghavi S, Wang X, Nogueras-Gonzalez G, Montalban-Bravo G, Borthakur G, DiNardo CD, Kadia T, Zhou L, Saenz D, Halim H, Alvarado Y, Ohanian M, Takahashi K, Short NJ, Jabbour E, Ravandi F, Garcia-Manero G, Pemmaraju N, Daver NG.   +23 more
europepmc   +1 more source